- Global Pharma News & Resources

Affimed Announces Second Quarter 2018 Financial Results and Corporate Update Conference Call

Heidelberg, Germany, August 3, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that on August 8, 2018, the Company will release its financial results for the quarter ended June 30, 2018. The Company's management team will host a conference call to discuss the Company's financial results and recent corporate developments on Wednesday, August 8, 2018 at 8:30 a.m. ET. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 6328006.

United States:  +1 323-794-2423
Germany:+49 (0)69 2222 2018
Netherlands:+31 (0)20 703 8261
Denmark:+45 35 15 81 21
France:+33 (0)1 76 77 22 57
Switzerland:+41 (0)22 567 5750
United Kingdom:   +44 (0)330 336 9411

An audio webcast of the conference call can be accessed in the "Events" section on the "Investors & Media" page of the Affimed website at . A replay of the webcast will be available on Affimed's website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.

About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit .

Affimed Investor Contact:
Gregory Gin, Head of Investor Relations

Affimed Media Contact:
Anca Alexandru, Head of Communications, EU IR

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Affimed N.V. via GlobeNewswire

Editor Details

Last Updated: 05-Aug-2018